 |
|||||||||
Thetford Mines, Quebec – TheNewswire – December 21, 2022 – KDA Group Inc. (TSXV:KDA) (“KDA” or the “Corporation”) is pleased to announce that it has acquired Covapharm Inc. (“Covapharm”) pursuant to a share purchase agreement (the “Share Purchase Agreement”) dated December 16, 2022, for a consideration of $200,000.00 payable in monthly instalments of $10,000.00 over a period of twenty (20) months from the closing date and a maximum of 1,825,000 Class A shares in the capital stock of the Corporation (the “KDA Shares”). The issuance of the KDA Shares is subject to the approval of the TSX Venture Exchange.
With this acquisition, the Corporation acquired the digital pharmacotherapy guide L’Apothicaire as well as the digital tool L’Assistant to optimize pharmaceutical treatment. These cutting-edge technologies will allow the Corporation to improve its technological product offering.
In addition, the Corporation will benefit from the services of Mr. Stéphane Côté, Covapharm’s executive officer, who led the development and implementation of L’Apothicaire and L’Assistant digital solutions. Mr. Côté will become a consultant to KDA, which will benefit from his skills, expertise and knowledge.
KDA and Covapharm’s shareholders are arm’s length parties and no finder’s fee is payable in connection with the transaction.
“We are pleased to have completed this strategic acquisition that will enable and bring to our technology platforms the technology additions and enhancements that this transaction will provide. This will further adapt our healthcare technology solutions to meet the needs of our customers. The expertise of KDA’s management will be further enhanced by the presence of Mr. Stéphane Côté (Pharmacist) who will definitely be a key strategic element that will complement our success”, said Marc Lemieux, Chief Executive Officer of KDA.
“KDA’s mission is to provide excellence at all times through the delivery of medical education and communications programs ranging from the development to the implementation of strategies offered to the pharmaceutical market in order to improve patient health,” added Mr. Lemieux.
KDA’S NEW IMAGE
KDA, an international leader in advanced medical technology solutions, recently unveiled its new brand image and website.
“Over the past few years, KDA has relied on innovation and the development of powerful and robust technologies to strengthen its position as an international leader in healthcare technology,” said Marc Lemieux, founder and CEO of KDA. “This is what gives us a head start in a changing and highly competitive market. Our new brand identity is a testament to this success and reflects our ambitions.”
ABOUT KDA GROUP
KDA Group is a leader in technological innovations and specialized solutions in the pharmaceutical market. KDA is a corporation that offers quality products and has a respected expertise among the various stakeholders in the pharmaceutical and medical sectors. Its management team is guided by the vision to pursue leading the way in Canada and internationally. Additional information about the Corporation is available at www.kdagroup.ca and on SEDAR at www.sedar.com.
– 30 –
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
INFORMATION
Marc Lemieux, Chief Executive Officer
514 622-7370
Copyright (c) 2022 TheNewswire – All rights reserved.
